Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) Stock Competitors & Peer Comparison
See SNSE's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SNSE and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SNSE | $13.85 | -22.28% | 18.6M | -0.10 | -$142.72 | N/A |
| VRTX | $538.90 | +2.03% | 140.1B | 29.01 | $19.03 | N/A |
| REGN | $829.41 | +2.37% | 86.6B | 18.43 | $45.63 | +0.44% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| MRNA | $134.31 | +113.33% | 69.2B | -21.40 | -$8.15 | N/A |
| ARGX | $1,034.94 | +4.22% | 64.2B | 93.22 | $11.08 | N/A |
| RVMDW | $12.00 | -4.65% | 48.6B | -1.72 | -$7.21 | N/A |
| RVMD | $212.27 | -1.73% | 45.6B | -24.34 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $370.89 | +0.47% | 40.3B | 66.35 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
SNSE vs VRTX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, VRTX has a market cap of 140.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while VRTX trades at $538.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas VRTX's P/E ratio is 29.01. In terms of profitability, SNSE's ROE is -1.93%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, SNSE is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
SNSE vs REGN Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, REGN has a market cap of 86.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while REGN trades at $829.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas REGN's P/E ratio is 18.43. In terms of profitability, SNSE's ROE is -1.93%, compared to REGN's ROE of +0.14%. Regarding short-term risk, SNSE is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
SNSE vs VRNA Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SNSE's ROE is -1.93%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, SNSE is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check VRNA's competition here
Moderna, Inc. (NASDAQ: MRNA)
SNSE vs MRNA Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, MRNA has a market cap of 69.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while MRNA trades at $134.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas MRNA's P/E ratio is -21.40. In terms of profitability, SNSE's ROE is -1.93%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, SNSE is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for SNSE.Check MRNA's competition here
argenx SE (NASDAQ: ARGX)
SNSE vs ARGX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ARGX has a market cap of 64.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ARGX trades at $1,034.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ARGX's P/E ratio is 93.22. In terms of profitability, SNSE's ROE is -1.93%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, SNSE is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
SNSE vs RVMDW Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, RVMDW has a market cap of 48.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while RVMDW trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas RVMDW's P/E ratio is -1.72. In terms of profitability, SNSE's ROE is -1.93%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, SNSE is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
SNSE vs RVMD Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, RVMD has a market cap of 45.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while RVMD trades at $212.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas RVMD's P/E ratio is -24.34. In terms of profitability, SNSE's ROE is -1.93%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, SNSE is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
SNSE vs SGEN Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SNSE's ROE is -1.93%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SNSE is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
SNSE vs ONC Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ONC has a market cap of 40.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ONC trades at $370.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ONC's P/E ratio is 66.35. In terms of profitability, SNSE's ROE is -1.93%, compared to ONC's ROE of +0.14%. Regarding short-term risk, SNSE is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
SNSE vs ALNY Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ALNY has a market cap of 32.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ALNY trades at $229.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ALNY's P/E ratio is 43.71. In terms of profitability, SNSE's ROE is -1.93%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, SNSE is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
SNSE vs BNTX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, BNTX has a market cap of 28.4B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while BNTX trades at $111.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas BNTX's P/E ratio is -20.47. In terms of profitability, SNSE's ROE is -1.93%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, SNSE is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
SNSE vs INSM Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, INSM has a market cap of 28.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while INSM trades at $125.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas INSM's P/E ratio is -28.59. In terms of profitability, SNSE's ROE is -1.93%, compared to INSM's ROE of -1.11%. Regarding short-term risk, SNSE is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
SNSE vs ROIV Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ROIV has a market cap of 27B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ROIV trades at $36.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ROIV's P/E ratio is -35.58. In terms of profitability, SNSE's ROE is -1.93%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, SNSE is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
SNSE vs INCY Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, INCY has a market cap of 26B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while INCY trades at $127.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas INCY's P/E ratio is 17.27. In terms of profitability, SNSE's ROE is -1.93%, compared to INCY's ROE of +0.30%. Regarding short-term risk, SNSE is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
SNSE vs UTHR Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, UTHR has a market cap of 22.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while UTHR trades at $521.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas UTHR's P/E ratio is 18.93. In terms of profitability, SNSE's ROE is -1.93%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, SNSE is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
SNSE vs GMAB Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, GMAB has a market cap of 20.9B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while GMAB trades at $33.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas GMAB's P/E ratio is 25.70. In terms of profitability, SNSE's ROE is -1.93%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, SNSE is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
SNSE vs BGNE Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SNSE's ROE is -1.93%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, SNSE is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
SNSE vs DNA-WT Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SNSE's ROE is -1.93%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, SNSE is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check DNA-WT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
SNSE vs BBIO Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, BBIO has a market cap of 16.4B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while BBIO trades at $83.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas BBIO's P/E ratio is -22.45. In terms of profitability, SNSE's ROE is -1.93%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, SNSE is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
SNSE vs ASND Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ASND has a market cap of 16.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ASND trades at $256.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ASND's P/E ratio is -107.28. In terms of profitability, SNSE's ROE is -1.93%, compared to ASND's ROE of +1.90%. Regarding short-term risk, SNSE is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ASND's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
SNSE vs JAZZ Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, JAZZ has a market cap of 15.8B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while JAZZ trades at $247.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas JAZZ's P/E ratio is 9.40. In terms of profitability, SNSE's ROE is -1.93%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, SNSE is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
SNSE vs NBIX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while NBIX trades at $153.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas NBIX's P/E ratio is 22.48. In terms of profitability, SNSE's ROE is -1.93%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, SNSE is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
SNSE vs EXEL Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, EXEL has a market cap of 13.7B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while EXEL trades at $53.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas EXEL's P/E ratio is 15.54. In terms of profitability, SNSE's ROE is -1.93%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, SNSE is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check EXEL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
SNSE vs BMRN Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, BMRN has a market cap of 13.4B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while BMRN trades at $67.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas BMRN's P/E ratio is 33.33. In terms of profitability, SNSE's ROE is -1.93%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, SNSE is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check BMRN's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
SNSE vs HALO Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, HALO has a market cap of 12.8B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while HALO trades at $106.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas HALO's P/E ratio is 20.08. In terms of profitability, SNSE's ROE is -1.93%, compared to HALO's ROE of +1.81%. Regarding short-term risk, SNSE is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
SNSE vs KRTX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SNSE's ROE is -1.93%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SNSE is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
SNSE vs ARWR Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ARWR has a market cap of 12.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ARWR trades at $87.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ARWR's P/E ratio is -39.74. In terms of profitability, SNSE's ROE is -1.93%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, SNSE is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
SNSE vs MDGL Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while MDGL trades at $526.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas MDGL's P/E ratio is -42.20. In terms of profitability, SNSE's ROE is -1.93%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, SNSE is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
SNSE vs TECH Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while TECH trades at $72.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas TECH's P/E ratio is 37.36. In terms of profitability, SNSE's ROE is -1.93%, compared to TECH's ROE of +0.09%. Regarding short-term risk, SNSE is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
SNSE vs RNAM Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SNSE's ROE is -1.93%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, SNSE is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
SNSE vs AXSM Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while AXSM trades at $207.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas AXSM's P/E ratio is -56.97. In terms of profitability, SNSE's ROE is -1.93%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, SNSE is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check AXSM's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
SNSE vs PRAX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, PRAX has a market cap of 10.8B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while PRAX trades at $369.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas PRAX's P/E ratio is -29.87. In terms of profitability, SNSE's ROE is -1.93%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, SNSE is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check PRAX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
SNSE vs KYMR Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, KYMR has a market cap of 10.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while KYMR trades at $122.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas KYMR's P/E ratio is -39.78. In terms of profitability, SNSE's ROE is -1.93%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, SNSE is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check KYMR's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
SNSE vs SMMT Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, SMMT has a market cap of 10.4B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while SMMT trades at $12.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas SMMT's P/E ratio is -8.18. In terms of profitability, SNSE's ROE is -1.93%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, SNSE is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
SNSE vs KRYS Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while KRYS trades at $338.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas KRYS's P/E ratio is 43.03. In terms of profitability, SNSE's ROE is -1.93%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SNSE is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check KRYS's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
SNSE vs IONS Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, IONS has a market cap of 10.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while IONS trades at $58.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas IONS's P/E ratio is -35.35. In terms of profitability, SNSE's ROE is -1.93%, compared to IONS's ROE of -1.11%. Regarding short-term risk, SNSE is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check IONS's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
SNSE vs PTGX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while PTGX trades at $149.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas PTGX's P/E ratio is 150.43. In terms of profitability, SNSE's ROE is -1.93%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, SNSE is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check PTGX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
SNSE vs CYTK Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, CYTK has a market cap of 9.7B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while CYTK trades at $77.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas CYTK's P/E ratio is -10.77. In terms of profitability, SNSE's ROE is -1.93%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, SNSE is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
SNSE vs RXDX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SNSE's ROE is -1.93%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SNSE is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check RXDX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
SNSE vs SYRE Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, SYRE has a market cap of 9.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while SYRE trades at $106.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas SYRE's P/E ratio is -55.86. In terms of profitability, SNSE's ROE is -1.93%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, SNSE is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
SNSE vs IMVT Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, IMVT has a market cap of 9.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while IMVT trades at $44.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas IMVT's P/E ratio is -15.94. In terms of profitability, SNSE's ROE is -1.93%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, SNSE is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check IMVT's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
SNSE vs NUVL Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas NUVL's P/E ratio is -21.79. In terms of profitability, SNSE's ROE is -1.93%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, SNSE is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
SNSE vs CRNX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while CRNX trades at $84.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas CRNX's P/E ratio is -16.80. In terms of profitability, SNSE's ROE is -1.93%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, SNSE is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check CRNX's competition here
Abivax S.A. (NASDAQ: ABVX)
SNSE vs ABVX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ABVX has a market cap of 8.9B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ABVX trades at $117.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ABVX's P/E ratio is -63.19. In terms of profitability, SNSE's ROE is -1.93%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, SNSE is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ABVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
SNSE vs IMGN Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SNSE's ROE is -1.93%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SNSE is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check IMGN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
SNSE vs PCVX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while PCVX trades at $61.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas PCVX's P/E ratio is -7.84. In terms of profitability, SNSE's ROE is -1.93%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, SNSE is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
SNSE vs IBRX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while IBRX trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas IBRX's P/E ratio is -8.38. In terms of profitability, SNSE's ROE is -1.93%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, SNSE is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check IBRX's competition here
Alkermes plc (NASDAQ: ALKS)
SNSE vs ALKS Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ALKS trades at $48.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ALKS's P/E ratio is 52.82. In terms of profitability, SNSE's ROE is -1.93%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, SNSE is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
SNSE vs BPMC Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SNSE's ROE is -1.93%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, SNSE is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
SNSE vs APGE Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while APGE trades at $134.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas APGE's P/E ratio is -31.11. In terms of profitability, SNSE's ROE is -1.93%, compared to APGE's ROE of -0.30%. Regarding short-term risk, SNSE is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
SNSE vs CERE Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas CERE's P/E ratio is -16.47. In terms of profitability, SNSE's ROE is -1.93%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SNSE is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check CERE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
SNSE vs RYTM Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while RYTM trades at $110.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas RYTM's P/E ratio is -37.21. In terms of profitability, SNSE's ROE is -1.93%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, SNSE is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check RYTM's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
SNSE vs TGTX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, TGTX has a market cap of 7.9B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while TGTX trades at $50.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas TGTX's P/E ratio is 18.73. In terms of profitability, SNSE's ROE is -1.93%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, SNSE is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check TGTX's competition here
Metsera, Inc. (NASDAQ: MTSR)
SNSE vs MTSR Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SNSE's ROE is -1.93%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, SNSE is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check MTSR's competition here
CG Oncology Inc. (NASDAQ: CGON)
SNSE vs CGON Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, CGON has a market cap of 7.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while CGON trades at $77.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas CGON's P/E ratio is -29.99. In terms of profitability, SNSE's ROE is -1.93%, compared to CGON's ROE of -0.25%. Regarding short-term risk, SNSE is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
SNSE vs MRUS Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SNSE's ROE is -1.93%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, SNSE is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check MRUS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
SNSE vs ORKA Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ORKA has a market cap of 6.8B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ORKA trades at $105.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ORKA's P/E ratio is -58.29. In terms of profitability, SNSE's ROE is -1.93%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, SNSE is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ORKA's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
SNSE vs SRRK Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, SRRK has a market cap of 6.8B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while SRRK trades at $55.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas SRRK's P/E ratio is -16.38. In terms of profitability, SNSE's ROE is -1.93%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, SNSE is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check SRRK's competition here
Belite Bio, Inc (NASDAQ: BLTE)
SNSE vs BLTE Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, BLTE has a market cap of 6.8B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while BLTE trades at $163.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas BLTE's P/E ratio is -90.13. In terms of profitability, SNSE's ROE is -1.93%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, SNSE is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check BLTE's competition here
Arcellx, Inc. (NASDAQ: ACLX)
SNSE vs ACLX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ACLX's P/E ratio is -28.27. In terms of profitability, SNSE's ROE is -1.93%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, SNSE is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
SNSE vs RETA Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas RETA's P/E ratio is -66.29. In terms of profitability, SNSE's ROE is -1.93%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SNSE is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check RETA's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
SNSE vs CAI Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, CAI has a market cap of 6.4B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while CAI trades at $24.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas CAI's P/E ratio is 63.95. In terms of profitability, SNSE's ROE is -1.93%, compared to CAI's ROE of +0.19%. Regarding short-term risk, SNSE is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
SNSE vs DNTH Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, DNTH has a market cap of 6.4B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while DNTH trades at $109.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas DNTH's P/E ratio is -27.40. In terms of profitability, SNSE's ROE is -1.93%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, SNSE is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
SNSE vs COGT Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, COGT has a market cap of 6.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while COGT trades at $35.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas COGT's P/E ratio is -17.46. In terms of profitability, SNSE's ROE is -1.93%, compared to COGT's ROE of -0.73%. Regarding short-term risk, SNSE is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check COGT's competition here
Erasca, Inc. (NASDAQ: ERAS)
SNSE vs ERAS Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ERAS trades at $17.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ERAS's P/E ratio is -19.43. In terms of profitability, SNSE's ROE is -1.93%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, SNSE is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ERAS's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
SNSE vs CNTA Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas CNTA's P/E ratio is -22.63. In terms of profitability, SNSE's ROE is -1.93%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, SNSE is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
SNSE vs MIRM Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while MIRM trades at $97.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas MIRM's P/E ratio is -7.03. In terms of profitability, SNSE's ROE is -1.93%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, SNSE is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check MIRM's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
SNSE vs PTCT Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while PTCT trades at $70.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas PTCT's P/E ratio is -31.62. In terms of profitability, SNSE's ROE is -1.93%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, SNSE is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check PTCT's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
SNSE vs TVTX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while TVTX trades at $64.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas TVTX's P/E ratio is -146.58. In terms of profitability, SNSE's ROE is -1.93%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, SNSE is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check TVTX's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
SNSE vs DFTX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, DFTX has a market cap of 6.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while DFTX trades at $45.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas DFTX's P/E ratio is N/A. In terms of profitability, SNSE's ROE is -1.93%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, SNSE is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check DFTX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
SNSE vs XENE Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, XENE has a market cap of 6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while XENE trades at $59.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas XENE's P/E ratio is -13.26. In terms of profitability, SNSE's ROE is -1.93%, compared to XENE's ROE of -0.44%. Regarding short-term risk, SNSE is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
SNSE vs LGND Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while LGND trades at $287.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas LGND's P/E ratio is 31.91. In terms of profitability, SNSE's ROE is -1.93%, compared to LGND's ROE of +0.20%. Regarding short-term risk, SNSE is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check LGND's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
SNSE vs CRSP Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, CRSP has a market cap of 5.8B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while CRSP trades at $58.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas CRSP's P/E ratio is -12.57. In terms of profitability, SNSE's ROE is -1.93%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, SNSE is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check CRSP's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
SNSE vs CDTX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SNSE's ROE is -1.93%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, SNSE is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
SNSE vs ABCM Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SNSE's ROE is -1.93%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SNSE is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
SNSE vs ISEE Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SNSE's ROE is -1.93%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SNSE is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
SNSE vs APLS Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas APLS's P/E ratio is 38.35. In terms of profitability, SNSE's ROE is -1.93%, compared to APLS's ROE of +0.40%. Regarding short-term risk, SNSE is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
SNSE vs ACAD Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ACAD has a market cap of 5.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ACAD trades at $29.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ACAD's P/E ratio is 13.61. In terms of profitability, SNSE's ROE is -1.93%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, SNSE is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
SNSE vs DYN Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, DYN has a market cap of 5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while DYN trades at $26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas DYN's P/E ratio is -8.32. In terms of profitability, SNSE's ROE is -1.93%, compared to DYN's ROE of -0.64%. Regarding short-term risk, SNSE is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check DYN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
SNSE vs EWTX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, EWTX has a market cap of 5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while EWTX trades at $43.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas EWTX's P/E ratio is -25.12. In terms of profitability, SNSE's ROE is -1.93%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, SNSE is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
SNSE vs TERN Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas TERN's P/E ratio is -51.41. In terms of profitability, SNSE's ROE is -1.93%, compared to TERN's ROE of -0.20%. Regarding short-term risk, SNSE is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check TERN's competition here
Veradermics, Incorporated (NYSE: MANE)
SNSE vs MANE Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while MANE trades at $102.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas MANE's P/E ratio is -35.42. In terms of profitability, SNSE's ROE is -1.93%, compared to MANE's ROE of -0.29%. Regarding short-term risk, SNSE is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check MANE's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
SNSE vs PBLS Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while PBLS trades at $39.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas PBLS's P/E ratio is -44.72. In terms of profitability, SNSE's ROE is -1.93%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, SNSE is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check PBLS's competition here
Celcuity Inc. (NASDAQ: CELC)
SNSE vs CELC Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, CELC has a market cap of 4.6B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while CELC trades at $91.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas CELC's P/E ratio is -21.78. In terms of profitability, SNSE's ROE is -1.93%, compared to CELC's ROE of -3.51%. Regarding short-term risk, SNSE is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check CELC's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
SNSE vs FOLD Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas FOLD's P/E ratio is -161.00. In terms of profitability, SNSE's ROE is -1.93%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, SNSE is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check FOLD's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
SNSE vs RLAY Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, RLAY has a market cap of 4.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while RLAY trades at $19.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas RLAY's P/E ratio is -13.21. In terms of profitability, SNSE's ROE is -1.93%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, SNSE is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check RLAY's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
SNSE vs AKRO Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SNSE's ROE is -1.93%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, SNSE is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
SNSE vs ALPN Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SNSE's ROE is -1.93%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SNSE is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ALPN's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
SNSE vs AMLX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, AMLX has a market cap of 4.3B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while AMLX trades at $40.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas AMLX's P/E ratio is -25.73. In terms of profitability, SNSE's ROE is -1.93%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, SNSE is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check AMLX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
SNSE vs ELVN Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ELVN trades at $58.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ELVN's P/E ratio is -35.56. In terms of profitability, SNSE's ROE is -1.93%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, SNSE is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ELVN's competition here
Opthea Limited (NASDAQ: OPT)
SNSE vs OPT Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas OPT's P/E ratio is -1.52. In terms of profitability, SNSE's ROE is -1.93%, compared to OPT's ROE of +1.18%. Regarding short-term risk, SNSE is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
SNSE vs PRTC Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas PRTC's P/E ratio is -3.78. In terms of profitability, SNSE's ROE is -1.93%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, SNSE is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check PRTC's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
SNSE vs VKTX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, VKTX has a market cap of 4.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while VKTX trades at $34.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas VKTX's P/E ratio is -8.69. In terms of profitability, SNSE's ROE is -1.93%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, SNSE is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check VKTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
SNSE vs LEGN Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, LEGN has a market cap of 4.2B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while LEGN trades at $21.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas LEGN's P/E ratio is -33.24. In terms of profitability, SNSE's ROE is -1.93%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, SNSE is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check LEGN's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
SNSE vs MRTX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SNSE's ROE is -1.93%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SNSE is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check MRTX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
SNSE vs TLX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, TLX has a market cap of 4.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while TLX trades at $12.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas TLX's P/E ratio is -658.70. In terms of profitability, SNSE's ROE is -1.93%, compared to TLX's ROE of -0.02%. Regarding short-term risk, SNSE is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check TLX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
SNSE vs TNGX Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while TNGX trades at $23.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas TNGX's P/E ratio is -30.36. In terms of profitability, SNSE's ROE is -1.93%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, SNSE is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check TNGX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
SNSE vs ADPT Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while ADPT trades at $25.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas ADPT's P/E ratio is -62.17. In terms of profitability, SNSE's ROE is -1.93%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, SNSE is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check ADPT's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
SNSE vs DNLI Comparison August 2026
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNSE stands at 18.6M. In comparison, DNLI has a market cap of 4.1B. Regarding current trading prices, SNSE is priced at $13.85 on the NASDAQ, while DNLI trades at $24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNSE currently has a P/E ratio of -0.10, whereas DNLI's P/E ratio is -8.92. In terms of profitability, SNSE's ROE is -1.93%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, SNSE is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for SNSE.Check DNLI's competition here